Related Experiment Video
Updated: Aug 7, 2026
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012
[I131 in blood samples: management in the laboratory]
J Vialard-Miguel1, J Mazère, S Mora
1Service de médecine nucléaire, CHU de Bordeaux, Hôpital du Haut-Lévêque, Pessac. julie.miguel@chu-bordeaux.fr
Objectives:
Patients treated by (131)I may require blood sampling in the days following its administration. We investigated the safety of such samples in terms of radioactivity and the possible disturbance of the analyses by these "131I-spiked" samples.
Method:
1) The radioactivity of blood samples from 131I-treated patients was measured (dose rate, surface activity, total activity) ; 2) The risk for the personnel was subsequently evaluated and ; 3) The interference of this 131I-generated radioactivity on the results of routine automated and IRMA assays was investigated.
Results:
1) All RA measures but two were found below the European limits ; 2) Irradiation of personnel was negligible ; 3) The faint radioactivity did not disturb any analyses.
Conclusion:
These data demonstrate the safety that results from the negligible radioactivity in these blood samples.
